Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele

Hematological Oncology

Volumn 28, Issue 2, 2010, Pages 98-103

  Xiao, Li ^a   Qiong, Liao ^a   Yan, Zhang ^a   Zheng, Zhang ^a   Luxi, Song ^a   Li, Xu ^a   Ying, Tao ^a   Yizhi, Liu ^a   Quan, Pu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acute myeloid leukaemia transformation; Bone marrow failure; Human leukocyte antigen (HLA); Myelodysplastic syndrome; PCR SSP

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA DR15 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW DEPRESSION; CD4 LYMPHOCYTE COUNT; CHILD; CHROMOSOME ABERRATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PANCYTOPENIA; POLARIZATION; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE COUNT;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BONE MARROW; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; DISEASE PROGRESSION; GENE FREQUENCY; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; MYELODYSPLASTIC SYNDROMES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953261858     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.907     Document Type: Article

References (21)

1. Baumann I, Scheid C, Koref MS, et al. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 2002; 30(12): 1405-1411
2. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102(5): 1314-1322
3. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100(5): 1570-1574 (Pubitemid 34925129)
4. Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001; 98(13): 3513-3519
5. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102(8): 3025-3027
6. Okamoto T, Okada M, Yamada S, et al. Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele. Leukemia 2000; 14(2): 344-346 (Pubitemid 30095397)
7. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasmas of the hematopoietic and lymphoid tissues; report of the Clinical Advisory Committee Meeting - Airlie House. Virginia. November,1997. Hematology J 2001; 1(1): 53-66
8. Bennett JM. World Health Organization classification of the acute leukemia and myelodysplastic syndrome. Int J Hematol 2000; 72(2): 131-137
9. Bennett JM, Catovsky D. Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51(21): 189-199
10. Version 2.2008, 09/06/07 ©2007 National Comprehensive Cancer Network, Inc
11. Marsh SG, Bodmer JG. HLA class-II nucleotide sequences. Tissue Antigens 1992; 39(3): 229-243
12. Olerup O, Zetterqueist H. HLA-DR typing by PCR-amplification with sequence primers in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39(3): 225-235
13. Jung T, Schauer U, Heusser C, et al. Detection of intracellular cytokines by flow cytometry. J Immunol Methods1993; 159(1-2): 197-207
14. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/ effector T cells by flow cytometry. Blood 1995; 86(4): 1408-1419
15. Sun Jl, Du KM, Fu M, et al. Statistical analysis of HLA polymorphism among 20596 stem cell donors of Han nationality. Chin J Blood Transfusion 2006; 19(5): 379-384
16. Greenberg P, Cox C, LeBeau MM, et al. International scoring system (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood 1997; 89: 2079-2088 (Pubitemid 27132124)
17. Wang RF. Identification of MHC class II-restricted tumor antigens recognized by CD4+T cells. Methods 2003; 29(3): 227-235
18. Oka Y, Tsuboi A, Murakami M, et al.Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78(1): 56-61
19. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17(7): 1301-1312
20. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11(12): 2049-2054 (Pubitemid 28043688)
21. Gersuk GM, Beckham C, Loken MR, et al. A role for tumor necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haemato 1998; 103(1): 176-188